The seed funding will support the commercialization of a platform designed to generate biomarker insights from pathology images without laboratory staining.

ViewsML, a company developing software for tissue analysis, announced the completion of an oversubscribed $4.9 million seed funding round led by Wittington Ventures. New investors Continuum Health Ventures and Mayo Clinic also participated, alongside repeat investors RiSC Capital, Debiopharm, WUTIF, Defined, and e-Fund.

The capital will be used to accelerate the commercialization of the company’s artificial intelligence-driven virtual biomarker staining platform. The company also plans to expand strategic partnerships, advance clinical validation of virtual biomarker panels, and grow its engineering, scientific, and commercial teams.

Virtual Staining Technology

The platform uses AI to generate per-cell biomarker spatial insights from pathology images without the need for traditional laboratory staining. As demand for high-resolution biomarker data increases in drug development and diagnostics, traditional staining workflows have become a bottleneck, according to the company.

The technology produces spatial biomarker insights from standard hematoxylin and eosin slides. This approach preserves scarce tissue samples while accelerating research, clinical trials, and patient care, according to a press release from the company.

“Biomarkers are foundational to how we understand and treat disease, yet the way we measure them remains constrained by legacy approaches. ViewsML is redefining how biomarkers are measured and analyzed, unlocking a step-change in speed, scale, and accessibility across research and clinical settings,” says Zeeshan Ali, partner, Wittington Ventures, in a release.

Accelerating Immunohistochemistry Workflows

By building a virtual biomarker library, the company aims to convert a traditionally lab-bound process into software. This shift enables an entirely new paradigm for assay development, according to the company.

“We’re building the computational layer for next-generation diagnostics, and are excited to partner with Wittington Ventures and work with Mayo Clinic to accelerate that vision,” says Kenneth To, ceo, ViewsML, in a release. “This capital will enable us to fast-track our efforts to revolutionize immunohistochemistry. By building the world’s first virtual biomarker library, we’re going to empower scientists and clinicians to analyze biomarker staining in minutes rather than the traditional days or weeks.”

ViewsML is presenting several poster sessions with partners at the American Association for Cancer Research Annual Meeting 2026, held in San Diego from April 17-22.

ID 429582737 © Yuri Arcurs | Dreamstime.com

Related Reading: